| NCT ID | NCT06602037 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RenJi Hospital |
| Condition | Neoplasms Pancreatic |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-11-20 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2024-11-20 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pancreatic cancer remains one of the most aggressive cancer types. Target-specific targeted therapy is an attractive therapeutic alternative for the treatment of patients with a wide range of cancers, including pancreatic cancer. Companion diagnostic technique is critical for the success of targeted therapies. SHR-A1921 is a TROP2-directed antibody-drug-conjugate (ADC) approved for several clinical trials for advanced solid tumors. SHR1920 is the humanized anti-Trop2 monoclonal antibody (hIgG1) of SHR-A1921. Radio-labeling SHR1920 with radionuclide Zirconium-89 (89Zr) enables non-invasive imaging and quantification of SHR-A1921 distribution in cancer patients. Performing a \[89Zr\]Zr-DFO-SHR1920 PET scan before treatment with SHR-A1921 can evaluate tracer uptake in the primary and metastatic tumor lesions and normal organ distribution. CLND18.2 is another potential therapeutic target for pancreatic cancer. Target-specific immunoPET imaging may help identify patients more likely to benefit from targeted therapy.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed diagnosis of pancreatic cancer or suspected pancreatic cancer by diagnostic imaging. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Exclusion Criteria: * Known or suspected hypersensitivity to SHR1920, DFO/RESCA/NOTA, 89Zr/18F or 68Ga or any of the excipients. * Pregnancy
Contact & Investigator
Jianjun Liu, PhD
STUDY CHAIR
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Frequently Asked Questions
Who can join the NCT06602037 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Neoplasms Pancreatic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06602037 currently recruiting?
Yes, NCT06602037 is actively recruiting participants. Contact the research team at wwei@shsmu.edu.cn for enrollment information.
Where is the NCT06602037 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06602037 clinical trial?
NCT06602037 is sponsored by RenJi Hospital. The principal investigator is Jianjun Liu, PhD at Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University. The trial plans to enroll 90 participants.